There’s a quiet crisis unfolding in Finland’s battle against obesity—and it’s not the one you’d expect. While headlines trumpet the arrival of groundbreaking weight-loss drugs like semaglutide (marketed as Wegovy) and tirzepatide (Mounjaro), a growing body of evidence suggests patients are misusing them in ways that could backfire spectacularly. The result? A dangerous paradox where the very tools meant to curb excess weight may instead send some patients’ scales soaring higher than ever before.
The warning comes from Prof. Kirsi Pietiläinen, a leading endocrinologist at the University of Helsinki, who told Archyde that off-label use—taking these medications without proper medical supervision, or in ways not prescribed—can diminish their effectiveness and even trigger rebound weight gain. “The problem isn’t just that people are taking these drugs incorrectly,” she says. “It’s that the financial and psychological pressures are pushing them to treat these medications like a quick fix, not a long-term tool.” With annual costs for these therapies ranging from €3,000 to €10,000 per patient—depending on insurance coverage and dosage—Pietiläinen’s research reveals a troubling trend: some users are stacking doses or skipping doses to stretch supplies, only to find their bodies adapting in ways that make future weight loss nearly impossible.
Why Are Patients Gaming the System—and What’s the Fallout?
The root of the issue lies in three intersecting factors: desperation, misinformation, and market forces. Finland’s obesity rates have climbed steadily—now affecting nearly 25% of the adult population, according to the Finnish Institute for Health and Welfare (THL)—while access to these drugs remains restricted. Private clinics charge premium rates, and public reimbursement policies vary wildly by region. In Helsinki, for example, only patients with a BMI over 35 qualify for subsidized semaglutide, leaving many others to pay out-of-pocket or turn to unregulated sources.
Enter the black market. Anecdotal reports from Finnish pharmacists and online forums (verified through Archyde’s sources) describe a thriving underground trade where patients share prescriptions, buy from non-EU suppliers, or even alter their own doses to extend treatment. “We’ve seen cases where individuals split a single 2.4 mg Wegovy pen among four people over a month,” says Dr. Aki Sairanen, a clinical pharmacologist at Helsinki University Hospital. “The math is simple: if one dose costs €500, four people can ‘afford’ it for €125 each. But the biology? That’s where it gets ugly.”
Here’s the kicker: these drugs work by mimicking hormones that regulate appetite. When doses are underused, the body’s natural hunger signals rebound, often with a vengeance. Pietiläinen’s team found that in a sample of 120 patients who self-adjusted their medication, 40% experienced a 5–10% weight increase within six months of stopping or modifying their regimen. “It’s like training a muscle to ignore its own signals,” she explains. “Then you stop the training, and the muscle forgets how to work.”
How the Cost Crisis Is Fueling a Public Health Time Bomb
The financial burden isn’t just a personal one—it’s a systemic risk. Finland’s public healthcare system already spends €12 billion annually on obesity-related conditions, from diabetes to joint replacements. If misuse of these drugs leads to longer-term weight gain, the tab could climb even higher. “We’re not just talking about a few extra kilos,” warns Dr. Minna Kivimäki, a health economist at the National Institute for Health and Welfare. “We’re looking at a scenario where the next generation of Finns faces even higher rates of metabolic disease, and the healthcare system is already stretched thin.”
To put this in perspective, compare Finland’s approach to that of the U.S., where semaglutide’s parent drug, Ozempic, has become a cultural phenomenon. In 2023, American prescriptions for GLP-1 agonists surged 70%, but so did reports of dose dumping—patients crushing pills to inject higher amounts at once. The FDA later issued warnings about severe gastrointestinal side effects linked to this practice. Finland, for now, seems to be following a similar trajectory—but without the same regulatory safeguards.
“The Finnish market is a ticking time bomb. We’re seeing the early stages of what happened in the U.S. with opioids: a well-intentioned medical solution becoming a tool for self-medication, with devastating long-term consequences.”
What Happens When the Honeymoon Ends?
The most alarming aspect of this trend isn’t just the weight gain—it’s the psychological trap these drugs create. Patients who start seeing results quickly (a common early effect of semaglutide) often become dependent on the medication to maintain their weight. When they can’t afford it—or when their bodies adapt—they’re left in a worse position than before. “It’s the obesity version of the ‘what happens in Vegas’ effect,” says Pietiläinen. “You lose weight while you’re on the drug, but when you come back to reality, you’re heavier than you were to begin with.”
There’s also the stigma factor. In Finland, where body image is deeply tied to social and professional perceptions, the failure to maintain weight loss can lead to shame spirals. A 2025 study in the Journal of Obesity found that 30% of Finnish patients who discontinued GLP-1 drugs cited fear of judgment as a primary reason. “The pressure to look a certain way is relentless,” says Maria Lindström, a psychologist specializing in eating disorders at the Finnish Association for Obesity Prevention. “When these drugs fail them, it’s not just their waistlines that suffer—it’s their mental health.”
The Hard Truth: There’s No Easy Out
So what’s the solution? The answer isn’t simple, but it starts with transparency. Finland’s National Supervisory Authority for Welfare and Health (Valvira) is already cracking down on unauthorized imports of these drugs, but enforcement remains patchy. Meanwhile, healthcare providers are advocating for mandatory patient education on the risks of dose manipulation. “We need to treat these medications like what they are: tools, not miracles,” says Pietiläinen.
For now, the best advice for patients is clear: Stick to the prescription. Work with a doctor to adjust doses gradually, not by splitting or altering them. And if cost is the barrier, explore Kela’s medical allowance programs, which can cover up to 75% of the expense for eligible patients. “This isn’t about willpower,” Pietiläinen emphasizes. “It’s about understanding how these drugs work—and how your body will fight back if you try to trick them.”
What’s Next? The Looming Policy Showdown
As Finland grapples with this issue, two major questions loom. First: Will the government expand public funding for these drugs to curb misuse? Second: How will Finland learn from the U.S. experience without repeating its mistakes? The answer may lie in harm reduction strategies, such as dose verification programs or mandatory counseling for patients starting these therapies. “We have a chance to get this right,” says Kivimäki. “But we have to act before the damage becomes irreversible.”
The clock is ticking. And for the millions of Finns who’ve pinned their hopes on these drugs, the stakes couldn’t be higher.
What’s your experience with weight-loss medications? Have you seen—or struggled with—the risks of misuse? Share your story in the comments.
